Non-Small Cell Lung Cancer | Oncology Today with Dr Neil Love: Management of MET-Altered Non-Small Cell Lung Cancer
Featuring an interview with Dr Rebecca Heist, including the following topics: Mechanism of action and toxicity of amivantamab in patients with MET-driven non-small cell lung cancer (NSCLC) (0:00) Potential role of MET inhibitors as pantumor treatment for MET-altered cancer (2:27) Selection and sequencing of targeted therapy for patients with MET-altered NSCLC (5:24) Managing MET-altered NSCLC in patients with brain metastases (7:55) Immune checkpoint inhibitors and MET-targeted therapy for patients with NSCLC and MET alterations (9:27) Case: A woman in her mid 60s with no smoking history and newly diagnosed NSCLC with a MET exon 14 skipping mutation (14:55) Case: A woman in her mid 70s with MET-amplified relapsed NSCLC with an EGFR L858R mutation (24:02) Novel agents and strategies for the management of MET-altered NSCLC (32:00) CME information and select publications